One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P®/Humate P® treatment in von Willebrand disease patients
- de Jager, N.C.B. (Nico C. B.)
- Bukkems, L.H. (Laura H.)
- Heijdra, J.M. (Jessica)
- Hazendonk, C.H.C.A.M. (Carolien H. C. A. M.)
- Fijnvandraat, K.
- Meijer, K. (Karina)
- Eikenboom, J.C.J. (Jeroen)
- Laros-Van Gorkom, B.A.P. (Britta)
- Leebeek, F.W.G. (Frank)
- Cnossen, M.H. (Marjon)
- Mathot, R.A. (Ron)
- Collins, P.W.
- Kruip, M.J.H.A. (Marieke)
- Polinder, S. (Suzanne)
- Lock, J. (J.)
- Moort, I. (Iris) van
- Goedhart, M.C.H.J. (M. C.H.J.)
- Coppens, M.
- Peters, M.A.D. (Marjolein)
- Preijers, T.
- Brons, P.P.
- Meer, F.J.M. (Felix) van der
- Schutgens, R. (Roger)
- Fischer, K. (Kathelijn)
- Driessens, M.H.E. (M. H.E.)
- Zwaan, C.M. (Michel)
- van Vliet, I. (I.)
- Liesner, R. (Ri)
- Chowdary, P. (P.)
- Keeling, D. (D.)
DOIAbstract
Introduction: Many patients with von Willebrand disease (VWD) are treated on demand with von Willebrand factor and factor VIII (FVIII) containing concentrates present with VWF and/or FVIII plasma levels outside set target levels. This carries a risk for bleeding and potentially for thrombosis. Development of a population pharmacokinetic (PK) model based on FVIII levels is a first step to more accurate on-demand perioperative dosing of this concentrate
Add to ORKG